Parag Rohit Sanghvi MD MSPH (He/Him)
Central Nervous System Cancer, Head & Neck, Hematologic Malignancies, Melanoma
Professor & Vice Chair Section Chief, Hematologic Malignancies Assistant Dean for Admissions Director, Professionalism in the Learning Environment UCSD School of Medicine
Join to View Full Profile
200 W Arbor DrSan Diego, CA 92103
Phone+1 800-926-8273
Dr. Sanghvi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Parag Sanghvi is a Professor and Vice Chair of Business Development in the department of Radiation Medicine and Applied Sciences at the University of California, San Diego. He specializes in the treatment of hematologic malignancies, cutaneous malignancies, HN cancers and brain tumors. He also serves as the Associate Program Director of the residency program.
Education & Training
Oregon Health & Science University (OHSU Health)Residency, Radiation Oncology, 2004 - 2008
University of WashingtonInternship, Internal Medicine, 2003 - 2004
Medical College of Georgia at Augusta UniversityClass of 2003
Certifications & Licensure
OR State Medical License 2007 - Present
CA State Medical License 2008 - 2026
WA State Medical License 2003 - 2004
American Board of Radiology Radiation Oncology
Publications & Presentations
PubMed
- 1 citationsProstate-Specific Antigen and Prostate Cancer in Gender-Affirming Hormone Therapy for Transgender or Nonbinary Individuals.Kylie M Morgan, Leah N Deshler, Michelle D Tibbs, Edmund M Qiao, Jennifer T Anger
International Journal of Radiation Oncology, Biology, Physics. 2025-03-01 - 1 citationsRedefining Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer Based on Relative Risk.Ryan T Morse, Tyler J Nelson, Hannah C Liu, Prangrawee Sangchan, Bhargava Chitti
International Journal of Radiation Oncology, Biology, Physics. 2025-03-01 - Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line...Dipesh Uprety, Devin Abrahami, Zachary A Marcum, Benjamin Li, Angela Sang
Lung Cancer. 2025-03-01
Press Mentions
Your Health: Questions to Ask Before SurgeryMarch 12th, 2023- New Radiation Therapy Option May Extend Lifespan, Improve Quality of Life for Certain Brain Cancer PatientsSeptember 19th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
